Latest Funding News

Entertainment Rewards Ltd reported a 12.7% increase in operating revenue for FY2025, driven by growth in key segments, but posted a wider net loss of $9.7 million amid higher expenses and a major convertible loan amendment.

Pure Hydrogen Corporation has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed market activity for the energy company.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.